公开(公告)号：US07811786B1

公开(公告)日：2010-10-12

申请号：US11579753

申请日：2004-06-11

申请人： Bong Yong Lee ,  Seung Kook Park ,  Shin Hye Park ,  Oh Byung Kwon ,  Chae Ha Yoon ,  Young Ju Kim ,  Song Young Kim ,  Kyung Hyun Min ,  Yoon Seok Lee ,  Tae Hee Lee ,  Tai Young Koo

发明人： Bong Yong Lee ,  Seung Kook Park ,  Shin Hye Park ,  Oh Byung Kwon ,  Chae Ha Yoon ,  Young Ju Kim ,  Song Young Kim ,  Kyung Hyun Min ,  Yoon Seok Lee ,  Tae Hee Lee ,  Tai Young Koo

IPC分类号： C12N15/00 ,  C12N1/20 ,  C12P21/06

CPC分类号： C12P21/02 ,  C12N15/70

摘要： Disclosed are a method of producing a target protein in a biologically-active, soluble form in prokaryotic cells and polycistronic vectors therefor.

摘要翻译： 公开了在原核细胞和多顺反子载体中生产生物活性的可溶形式的靶蛋白的方法。

公开(公告)号：US06541619B1

公开(公告)日：2003-04-01

申请号：US09530685

申请日：2000-07-13

申请人： Myung-Hwan Park ,  Seung-Kook Park ,  Jong-Myung Yoon ,  Seung-Hee Han ,  Byung-Kwon Oh ,  Seung-Ho Kim ,  Young-Man Kim ,  Tai-Young Koo ,  Byoung-Kwang Lee

发明人： Myung-Hwan Park ,  Seung-Kook Park ,  Jong-Myung Yoon ,  Seung-Hee Han ,  Byung-Kwon Oh ,  Seung-Ho Kim ,  Young-Man Kim ,  Tai-Young Koo ,  Byoung-Kwang Lee

IPC分类号： C12N1509

CPC分类号： C07K14/485 ,  A61K38/00 ,  C07K14/515 ,  C07K2319/00

摘要： The present invention provides a genetically engineered fusion protein consisting of hEGF that is internalized inside of the cells after tracing down the cancer cells expressing hEGF receptors and human angiogenin that is cytotoxic by degrading ribonucleotide upon internalization, a process for preparing a fusion protein in a large quantity by transforming E. coli with the expression vectors containing the gene encoding the fusion protein, and pharmaceutical application of the fusion protein as an anticancer agent. All components of the fusion protein form no antibodies and exhibit no immunotoxicity since they are derived from human. Each component alone is inactive to the cancer cells, however, once they are fused together, they kill the cancer cells selectively with a difference of 1000 fold in IC50 in spite of its low molecular weight. Therefore, the fusion protein of the present invention is capable of treating the cancer expressing hEGF receptors at high level without showing toxicity.

摘要翻译： 本发明提供由hEGF构成的遗传工程改造的融合蛋白，其在追踪表达hEGF受体的癌细胞和通过内化后降解核糖核苷酸而细胞毒性的人血管生成素下追踪细胞内部化，在大量制备融合蛋白的方法 通过用包含编码融合蛋白的基因的表达载体转化大肠杆菌的量和融合蛋白作为抗癌剂的药物应用。 融合蛋白的所有组分不形成抗体并且不表现出免疫毒性，因为它们衍生自人。 每个组分单独对癌细胞无活性，然而，一旦它们融合在一起，尽管其分子量低，它们以IC50的差异有选择地杀死癌细胞。 因此，本发明的融合蛋白能够以高水平治疗表达hEGF的癌症受体，而不显示毒性。